RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains

Simply Wall St.06-10 09:25

AdvertisementRemeGen stock overview after recent performance moves RemeGen (SEHK:9995) has drawn fresh attention after a mixed run in its share price, with a small gain over the past day contrasting ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642412452?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-10 09:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642412452","market":"hk","top_or_hot":-1,"title":"RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRemeGen stock overview after recent performance moves RemeGen (SEHK:9995) has drawn fresh attention after a mixed run in its share price, with a small gain over the past day contrasting ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-valuation-check-after-recent-share-price-we\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-10 09:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-valuation-check-after-recent-share-price-we><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRemeGen stock overview after recent performance moves RemeGen (SEHK:9995) has drawn fresh attention after a mixed run in its share price, with a small gain over the past day contrasting ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-valuation-check-after-recent-share-price-we\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-valuation-check-after-recent-share-price-we","article_id":"2642412452","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-valuation-check-after-recent-share-price-we","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2642412452","pubTimestamp":1781054700,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"RemeGen stock overview after recent performance moves\nRemeGen (SEHK:9995) has drawn fresh attention after a mixed run in its share price, with a small gain over the past day contrasting with declines over the past week, month and past 3 months.\nSee our latest analysis for RemeGen.\nZooming out, RemeGen’s 1-year total shareholder return of 44.42% and 3-year total shareholder return of 121.60% contrast with a recent 30-day share price return that is down 29.12%, suggesting momentum has cooled...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","09995":"荣昌生物","BK1161":"生物科技","BK1574":"生物医药B类股","BK1583":"高瓴概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"RemeGen(SEHK：9995)在近期股价疲软和多年上涨后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":0.9,"DCF":1},"content_text":"AdvertisementRemeGen stock overview after recent performance moves RemeGen (SEHK:9995) has drawn fresh attention after a mixed run in its share price, with a small gain over the past day contrasting with declines over the past week, month and past 3 months. See our latest analysis for RemeGen. Zooming out, RemeGen’s 1-year total shareholder return of 44.42% and 3-year total shareholder return of 121.60% contrast with a recent 30-day share price return that is down 29.12%, suggesting momentum has cooled after a strong multi year run. If you are weighing RemeGen against other healthcare opportunities, it can be useful to see what else is moving in the sector via 133 healthcare AI stocks. With RemeGen trading at a discount to both one valuation estimate and an external price target despite recent share price weakness, the key question is whether this reflects a genuine opportunity or a market that has already priced in future growth. Price-to-Earnings of 26x: Is it justified? RemeGen trades on a P/E of 26x, which, based on several checks, points to a stock that screens as undervalued against some benchmarks yet expensive against others. The P/E ratio compares the current share price to earnings per share and is a quick way to see how much investors are paying for each unit of profit. For a biopharmaceutical company that has only recently become profitable, this measure gives a snapshot of how the market is currently viewing its earnings power. On one side, RemeGen is described as trading at 45.8% below one fair value estimate, and its P/E of 26x is lower than both the Asian biotechs industry average of 29.9x and a peer average of 53.4x. On the other side, the same P/E of 26x is considered expensive relative to an estimated fair P/E of 16.4x. This is a level the market could move towards if sentiment or growth expectations cool. Explore the SWS fair ratio for RemeGen Result: Price-to-Earnings of 26x (ABOUT RIGHT) However, this picture can change quickly if recent share price weakness deepens or if expectations around RemeGen’s drug pipeline and clinical progress cool materially. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. Another angle on value: cash flows versus earnings The earlier P/E check presents a mixed picture, but the SWS DCF model result appears more one sided. With RemeGen at HK$69.25 and the DCF estimate at HK$127.84, the shares are described as trading at a 45.8% discount. This sends a very different signal compared with the 26x P/E. When one method suggests possible overpricing and another indicates a large discount, which one should carry more weight in the assessment? Look into how the SWS DCF model arrives at its fair value. 9995 Discounted Cash Flow as at Jun 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out RemeGen for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 203 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Does this combination of recent weakness and longer-term gains leave you confident or cautious? Act while the data is fresh, review the full picture, and consider the 3 key rewards and 2 important warning signs Looking for more investment ideas? If you stop here, you risk missing stocks that better fit your goals, so keep going and turn this research session into a broader opportunity hunt.  Spot fresh opportunities early by scanning screener containing 504 high quality undiscovered gems that combine quality fundamentals with the potential to surprise the market. Strengthen your portfolio’s foundation by zeroing in on companies in the solid balance sheet and fundamentals stocks screener (408 results) that pair financial resilience with underlying business strength. Dial back volatility without tuning out returns by focusing on 278 resilient stocks with low risk scores that score well on stability and downside protection.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642412452","isCrawlerRequest":true}